First Participants Randomized in AskBio Phase II Gene Therapy Trial for Parkinson’s Disease

On January 14, 2025, AskBio reached a pivotal milestone in the fight against Parkinson’s disease by randomizing the first participants in its Phase II gene therapy trial. This trial represents a crucial phase in the development of AAV (Adeno-Associated Virus) gene therapy technology and therapeutics, aiming to offer new hope to those affected by Parkinson’s disease. The randomization of participants is a key step in ensuring the trial's integrity and the reliability of its outcomes, as it helps to eliminate bias and ensures that the results are statistically valid. This development underscores AskBio's commitment to advancing gene therapy as a viable treatment option for neurodegenerative diseases.